Amanat Acquisition To Merge With Corxel Pharmaceuticals; Transaction Includes Concurrent, Oversubscribed PIPE With Expected Gross Proceeds Of ~$300M In Addition To ~$75M In Amanat’s Trust Account
Transaction OverviewThe proposed business combination and concurrent PIPE are expected to provide approximately $377 million (prior to the payment of transaction costs and assuming no redemptions by Amanat’s
Two companies are joining together and raising about $377 million. This money will help them grow, so watch if they use it wisely on their medicines.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.